ライフサイエンスコーパス: sarcomatoid

1 nrolled (75% epithelioid and 25% biphasic or sarcomatoid).

2 en malignant mesotheliomas (10 epithelial, 1 sarcomatoid).

3 tologic subtypes: epithelioid, biphasic, and sarcomatoid.

4 Histological analysis showed prostatic sarcomatoid and basaloid carcinomas with massive squamou

5 In the remainder, sarcomatoid and carcinomatous elements shared 42% of som

6 ncing including patients with microdissected sarcomatoid and epithelial components.

7 Sarcomatoid and rhabdoid (S/R) renal cell carcinoma (RCC

8 Single-nuclei RNA sequencing of the adverse sarcomatoid and rhabdoid phenotypes uncover gene signatu

9 phasic-epithelioid (biphasic-E) and biphasic-sarcomatoid (biphasic-S).

10 Pulmonary sarcomatoid carcinoma (PSC) contains carcinomatous compo

11 cinar cell carcinoma, ductal adenocarcinoma, sarcomatoid carcinoma and neuroendocrine tumors, and all

12 e that developed, which progressed to lethal sarcomatoid carcinoma at approximately 6 months of age.

13 atic, with many characteristics of pulmonary sarcomatoid carcinoma, a neoplasm previously undocumente

14 atic neuroendocrine tumour, n = 15), and SC (sarcomatoid carcinoma, n = 7).

15 Pulmonary sarcomatoid carcinomas (PSC) are a rare group of lung ca

16 splay aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumab

17 thelial to mesenchymal transition in vivo to sarcomatoid carcinomas containing osseous metaplasia.

18 often included under the broader concept of sarcomatoid carcinomas.

19 Sarcomatoid clear-cell renal cell carcinomas (sRCC) are

20 th renal cell carcinoma with a clear cell or sarcomatoid component and increased risk of recurrence.

21 cal confirmation of clear cell, papillary or sarcomatoid component were randomized in a 2:1 fashion t

22 more aggressive management than RCC without sarcomatoid components (nsRCC).

23 PDL1 expression is increased in sarcomatoid dedifferentiated renal tumours, which sugges

24 Genomic alterations associated with sarcomatoid dedifferentiation are poorly characterized.

25 Sarcomatoid dedifferentiation is an uncommon feature tha

26 st described in 1968, the mechanisms driving sarcomatoid dedifferentiation remain poorly understood,

27 and 50% in patients with clear cell RCC with sarcomatoid differentiation and 26% in patients with var

28 Patients who have mRCC and sarcomatoid differentiation can demonstrate objective re

29 Sarcomatoid differentiation in RCC (sRCC) is associated

30 g accuracy of 70% in the task of identifying sarcomatoid differentiation in RCC on standard multipara

31 Metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation is an aggressive disease tha

32 ear-cell histology and a lower percentage of sarcomatoid differentiation may have better outcomes wit

33 cal need for a non-invasive method to detect sarcomatoid differentiation pre-operatively.

34 toid tumor presence (PFS: ratio of HR for no sarcomatoid differentiation to HR for sarcomatoid differ

35 for no sarcomatoid differentiation to HR for sarcomatoid differentiation, 1.54; 95% CI, 1.07-2.21).

36 BMPC cancers lacked neuroendocrine or sarcomatoid differentiation, features uncommon in human

37 ith variant histology RCC or RCC with >= 20% sarcomatoid differentiation.

38 t histology or any RCC histology with >= 20% sarcomatoid differentiation.

39 were reviewed to determine the percentage of sarcomatoid differentiation.

40 Most interestingly, sarcomatoid elements acquired biallelic tumor protein p5

41 otein 1 (BAP1) were significantly mutated in sarcomatoid elements and were mutually exclusive with TP

42 These findings provide evidence that sarcomatoid elements arise from dedifferentiation of car

43 Sarcomatoid elements had a higher overall SSNV burden (m

44 t frequent SSNVs shared by carcinomatous and sarcomatoid elements were in known ccRCC genes including

45 lying clear-cell histology and less than 20% sarcomatoid elements.

46 identified four distinct molecular subtypes: sarcomatoid, epithelioid, biphasic-epithelioid (biphasic

47 Renal cell carcinoma with sarcomatoid features (sRCC) is a highly aggressive tumor

48 %, intermediate-risk/poor-risk 25.0%, and by sarcomatoid features 36.4%.

49 The presence of sarcomatoid features in clear cell renal cell carcinoma

50 Patients who had mRCC with sarcomatoid features in the primary tumor and who were t

51 The median percentage of sarcomatoid features was 14% (range, 3% to 90%).

52 stases, brain metastases, or the presence of sarcomatoid features.

53 synergize with Kras(G12D) to cause PDAC with sarcomatoid features.

54 metinib and AZD8186 in patients with MM with sarcomatoid features.

55 The sarcomatoid group had significantly shorter median recur

56 patients with epithelial (H2461 and H2591), sarcomatoid (H2373), and biphasic (MSTO-211H) MPM.

57 Sarcomatoid HCC is a rare histological subtype of HCC wi

58 Only 47.5% of the patients with sarcomatoid HCC presented with typical image patterns of

59 onclusion: Compared with nonsarcomatoid HCC, sarcomatoid HCC was associated with more advanced histol

60 The pathological grading of sarcomatoid HCC was more advanced compared with that of

61 Among them, 40 patients with sarcomatoid HCC were identified from the pathology datab

62 The majority of these patients with sarcomatoid HCC were men (75%); their median age was 58

63 manifestations and outcomes of patients with sarcomatoid HCC.

64 Patients with fibrolamellar carcinoma, sarcomatoid hepatocellular carcinoma, or combined hepato

65 renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk dis

66 , patients with a component of clear cell or sarcomatoid histology and who were previously untreated,

67 ORR for patients with Fuhrman grade 4 and/or sarcomatoid histology was 22% (n = 18; 95% CI, 6% to 48%

68 aplastic components of spindle, squamous, or sarcomatoid histology.

69 tro and in vivo against both epithelioid and sarcomatoid mesothelioma.

70 xtended survival, it paradoxically increased sarcomatoid metastases.

71 ed primary liver tumor incidence and enabled sarcomatoid metastasis.

72 loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in s

73 d MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subt

74 of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therape

75 istological types: epithelioid, biphasic and sarcomatoid MM.

76 Some RCCs had a sarcomatoid morphology of spindle cells in whorled patte

77 cases, with lower mutation rates observed in sarcomatoid MPM (P < 0.001).

78 T formation in biphasic subtype MPM, but not sarcomatoid MPM, independent of effects on cell number.

79 Forty-three patients who had sarcomatoid mRCC were identified.

80 patients (78%), including three with either sarcomatoid or biphasic MPM.

81 nce was strongly associated with an EMT-like sarcomatoid phenotype and high expression of the Abcb1b

82 eration, migration, and transition to a more sarcomatoid phenotype in subsets of mesothelioma cell li

83 if harboring pure squamous, adenocarcinoma, sarcomatoid, plasmacytoid, or micropapillary disease.

84 phic giant cells with an immunohistochemical sarcomatoid profile were present in the undifferentiated

85 We report the outcomes of 31 patients with sarcomatoid RCC treated with a combination of surgical r

86 the cases of 31 consecutive patients in whom sarcomatoid RCC was diagnosed between 1990 and 1997.

87 d classification, five chromophobe RCC, five sarcomatoid RCC, two oncocytomas, three transitional cel

88 Historically, conventional treatments for sarcomatoid RCCs (sRCCs) have shown little efficacy, and

89 otherapy may play a role in the treatment of sarcomatoid RCCs in select patients.

90 A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrec

91 A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrec

92 (i.e., high grade clear cell carcinomas and sarcomatoid renal tumors) show aberrant expression of ca

93 A146T and Q61H mutations in 2 out of 4 (50%) sarcomatoid SDC variants.

94 ied with histological reminiscences to human sarcomatoid SDC variants.

95 e sequencing of matched normal-carcinomatous-sarcomatoid specimens from 21 subjects.

96 elial differentiation (i.e., micropapillary, sarcomatoid, squamous/glandular differentiation, etc.),

97 portional hazard model revealed histological sarcomatoid subtype as an independent factor for all-cau

98 Histological sarcomatoid subtype is an independent predictor of tumor

99 Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresis

100 uamous, and extracellular matrix proteins in sarcomatoid subtypes.

101 Escaping tumors contained areas of sarcomatoid transformation with disappearance of CAFs.

102 ariate analysis, age, sex, and percentage of sarcomatoid tumor (< or >50%) did not significantly corr

103 idly and specifically target epithelioid and sarcomatoid tumor cells, demonstrating the potential of

104 vels of PD-L1 expression, and the absence of sarcomatoid tumor differentiation are associated with a

105 te risk score, 0.96; 95% CI, 0.70-1.30), and sarcomatoid tumor presence (PFS: ratio of HR for no sarc

106 Adjusting for age, sex, and percentage of sarcomatoid tumor, the relative risk of death was 10.4 t

107 Sarcomatoid tumors exhibit lower prevalence of PBRM1 mut

108 Patients with sarcomatoid tumors relapsed earlier than other subtypes

109 atify patients, explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiang

110 n of P-glycoprotein could partly resensitize sarcomatoid tumors to the PARP inhibitor olaparib, docet

111 een patients had epithelioid tumors, two had sarcomatoid tumors, and 10 had biphasic tumors.

112 Treatment outcomes for sarcomatoid tumours have remained relatively consistent

113 t interact with KRAS to initiate aggressive, sarcomatoid-type ICC revealed that tumor growth relies o

114 ar cell, mixed granular cell/clear cell, and sarcomatoid types) but also in papillary RCC, a less fre

115 f mesothelioma of both epithelioid (M28) and sarcomatoid (VAMT-1) origins.

116 Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis.

117 Sarcomatoid variants of renal cell carcinoma (RCC) are a

118 btype with the best prognosis), biphasic and sarcomatoid (worst prognosis).